Oral Estradiol Legal and Patent Challenges: FDA History, Label Updates, and Safety Disputes

See the public record for Estradiol

At a glance

  • FDA request to rewrite warnings / 2025-11-10 [1]
  • First six updated labels approved / 2026-02-12 [2]
  • Oral estradiol tablets / older boxed warning still in place [4]
  • Estradiol patches / Climara and Vivelle-Dot still carry the longer wording [5][6]
  • Endometrial cancer boxed warning / FDA asked manufacturers to keep it on systemic estrogen-alone products [1]
  • Lowest effective dose wording / FDA asked makers to remove it [1]
  • Trial behind the 2003 warning / WHI used conjugated equine estrogens, not estradiol [7][8]
  • Clot risk by route / oral odds ratio 2.5 vs transdermal 1.2, observational [9]

What did FDA change in November 2025?

On 2025-11-10 FDA asked application holders for menopausal hormone therapy to make five labeling changes: remove boxed-warning language on cardiovascular disease, breast cancer and probable dementia; remove the endometrial cancer boxed language except on systemic estrogen-alone products; remove the recommendation to use the lowest effective dose for the shortest time; add consideration of starting therapy for moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause; and add WHI data for women aged 50 to 59 [1].

FDA said cardiovascular and breast cancer information stays elsewhere in the labeling, and that the dementia language was removed because the WHI dementia studies enrolled women aged 65 to 79 [1].

Which products have new labels so far?

On 2026-02-12 FDA approved the first six updated labels: Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva, spanning systemic combination therapy, systemic estrogen-alone therapy, progestogen-alone therapy and topical vaginal estrogen [2][3]. FDA said 29 companies had submitted proposed changes [2].

Oral estradiol tablets are not on that list. The Teva oral estradiol tablet label, effective 2024-02-01, still carries the older boxed warning headed 'ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER' and 'CARDIOVASCULAR AND OTHER RISKS' [4][3].

The Climara and Vivelle-Dot patch labels also still carry boxed warnings covering endometrial cancer, cardiovascular disorders, probable dementia and breast cancer [5][6].

Divigel's updated label carries a shorter boxed warning about endometrial cancer with unopposed estrogen in women with a uterus [10]. Updates are arriving product by product, not as one class-wide switch.

What the WHI actually tested

The Women's Health Initiative tested conjugated equine estrogens, not estradiol. The WHI estrogen-plus-progestin trial enrolled 16,608 women aged 50 to 79 with a uterus: 8,506 received conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily, and 8,102 received placebo. It stopped at a mean of 5.2 years. Hazard ratios were 1.29 for coronary heart disease, 1.26 for invasive breast cancer, 1.41 for stroke and 2.13 for pulmonary embolism [7]. The WHI estrogen-alone trial enrolled 10,739 postmenopausal women aged 50 to 79 with a prior hysterectomy, assigned to conjugated equine estrogen 0.625 mg daily or placebo; it ran an average of 6.8 years and reported a hazard ratio of 1.39 for stroke [8].

The labels say this themselves. The patch boxed warning states that only daily oral conjugated estrogens 0.625 mg were studied in the estrogen-alone substudy, so the relevance of those findings to lower doses, other routes of administration or other estrogen-alone products is not known, and the risks cannot be definitively excluded [5]. Following the WHI results, FDA began approving class-wide labeling changes in 2003, which came to include the boxed warning [1].

The clot dispute: oral versus transdermal

ESTHER, a French multicenter case-control study of women aged 45 to 70 recruited between 1999 and 2005, compared 271 women with a first idiopathic venous thromboembolism against 610 matched controls. Adjusted odds ratios for VTE in current users versus nonusers were 4.2 (95% CI 1.5 to 11.6) for oral estrogen and 0.9 (0.4 to 2.1) for transdermal estrogen [11]. It was observational, not randomized.

A 2008 BMJ systematic review pooled eight observational studies and nine randomized trials. In the observational data the odds ratio for a first VTE was 2.5 (1.9 to 3.4) for oral estrogen and 1.2 (0.9 to 1.7) for transdermal, with oral risk highest in the first year of use at 4.0 (2.9 to 5.7) [9].

The transdermal findings come from observational studies, not randomized trials. The Climara label lists active DVT or PE, or a history of either, as a contraindication. Its Warnings and Precautions section reports WHI figures for conjugated estrogens rather than estradiol: VTE 30 versus 22 per 10,000 women-years with estrogen alone, with the difference in DVT (23 versus 15) statistically significant [5].

Cognition and the timing question

ELITE's cognitive analysis included 567 women who received oral 17-beta estradiol 1 mg daily or placebo, with a mean treatment duration of 57 months; women with a uterus also received cyclic micronized progesterone vaginal gel or placebo gel. The verbal memory difference was -0.06 (95% CI -0.22 to 0.09), p=0.33, with no significant differences in executive function or global cognition, and results were similar in women within 6 years of menopause and those 10 or more years past it [12].

KEEPS-Cog followed 693 recently postmenopausal women (mean age 52.6, about 1.4 years past their last period) for 4 years: 220 took oral conjugated equine estrogens 0.45 mg daily, 211 took transdermal estradiol 50 mcg daily, each with micronized progesterone 200 mg for 12 days a month, and 262 took placebo. There was no treatment-related benefit on cognition. Oral conjugated equine estrogens improved depression and anxiety scores; transdermal estradiol was similar to placebo. The authors cautioned that results cannot be extended beyond 4 years [13].

ELITE's vascular arm measured carotid intima-media thickness in 643 women. In the early-postmenopause stratum, thickness increased 0.0078 mm per year on placebo versus 0.0044 mm per year on estradiol (P=0.008); in the late stratum the rates were 0.0088 and 0.0100 mm per year (P=0.29), with a significant interaction between strata (P=0.007) [14].

Compounded oral estradiol

Compounded estradiol is not FDA-approved. FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed, and says compounded drugs should be used only when a patient's needs cannot be met by an FDA-approved drug; FDA-approved estradiol tablets and patches exist [15].

Oversight is split. State boards of pharmacy generally have primary responsibility for day-to-day oversight of state-licensed pharmacies, while facilities registered with FDA as outsourcing facilities are inspected by FDA on a risk-based schedule and must follow current good manufacturing practice [15].

Frequently asked questions

Do oral estradiol tablets still have a boxed warning?
Yes. The Teva oral estradiol tablet label in DailyMed still carries the older boxed warning headed 'ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER' and 'CARDIOVASCULAR AND OTHER RISKS' [4]. In its 2025 request, FDA asked manufacturers to keep the endometrial cancer boxed warning on systemic estrogen-alone products [1].
Did the FDA remove the boxed warning from estradiol patches?
Not from the Climara and Vivelle-Dot labels. They still carry a boxed warning covering endometrial cancer, cardiovascular disorders, probable dementia and breast cancer [5][6], and the FDA list of updated prescribing information as of 2026-02-12 does not name estradiol patches [3].
Was oral estradiol the estrogen tested in the WHI?
No. The WHI used conjugated equine estrogens 0.625 mg, alone or with medroxyprogesterone acetate 2.5 mg [7][8]. The patch label states that the relevance of those findings to other routes of administration and other estrogen-alone products is not known [5].
Does transdermal estradiol avoid the clot risk of oral estradiol?
Observational data point that way but do not settle it. In ESTHER the odds ratio for a first VTE was 4.2 for oral estrogen and 0.9 for transdermal [11]; a 2008 meta-analysis of observational studies found 2.5 and 1.2 [9]. The transdermal findings are not from randomized trials, and the Climara label still lists active DVT or PE as a contraindication [5].
What did FDA ask hormone therapy makers to change?
Remove boxed-warning language on cardiovascular disease, breast cancer and probable dementia; keep the endometrial cancer boxed warning on systemic estrogen-alone products; drop the lowest effective dose for the shortest time recommendation; add consideration of starting therapy for moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause; and add WHI data for women aged 50 to 59 [1].
Is compounded oral estradiol FDA-approved?
No. FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed, and says compounded drugs should be used only when a patient's needs cannot be met by an FDA-approved drug [15].

References

Show all 16 referencesHide references
  1. U.S. Food and Drug Administration.
  2. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products | FDA.
  3. Menopausal Hormone Therapies with Updated Prescribing Information | FDA.
  4. U.S. National Library of Medicine, DailyMed. Estradiol tablets USP (Teva) prescribing information. Estradiol tablets USP (Teva) label
  5. U.S. National Library of Medicine, DailyMed. Climara estradiol transdermal system (Bayer) prescribing information. Climara estradiol transdermal system (Bayer) label
  6. U.S. National Library of Medicine, DailyMed. Vivelle-Dot estradiol transdermal system (Sandoz) prescribing information. Vivelle-Dot estradiol transdermal system (Sandoz) label
  7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.
  8. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-12.
  9. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227-31.
  10. U.S. National Library of Medicine, DailyMed. Divigel estradiol gel (shortened boxed warning, for contrast) prescribing information. Divigel estradiol gel (shortened boxed warning, for contrast) label
  11. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-5.
  12. Henderson VW, St John JA, Hodis HN, McCleary CA, Stanczyk FZ, Shoupe D, et al. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. Neurology. 2016;87(7):699-708.
  13. Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Med. 2015;12(6):e1001833; discussion e1001833.
  14. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016;374(13):1221-31.
  15. Compounding and the FDA: Questions and Answers | FDA.
  16. FDA Update on Estradiol Transdermal Patch Availability | FDA.
Evidence overview for Oral Estradiol Legal and Patent Challenges: FDA History, Label Updates, and Safety Disputes